PEPCID AC (famotidine) by Dr. Reddy's Laboratories is histamine h2 receptor antagonists [moa]. First approved in 1995.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
PEPCID AC (famotidine) is an oral H2-receptor antagonist that reduces gastric acid production by blocking histamine signaling in the stomach. It is indicated for the treatment and prevention of heartburn, acid indigestion, and gastric ulcers. The drug works by competitively inhibiting histamine H2 receptors on parietal cells, thereby decreasing acid secretion.
As LOE approaches, the brand team is likely focused on lifecycle extension, generic defense, and transition planning rather than growth initiatives.
Histamine H2 Receptor Antagonists
Histamine-2 Receptor Antagonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.
Worked on PEPCID AC at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PEPCID AC as a pharma professional offers stability in a mature, well-understood market but limited growth upside; roles emphasize cost efficiency, generic competition management, and line extension strategy. This is ideal for professionals seeking deep expertise in lifecycle management and OTC commercialization rather than launch excitement or novel mechanism development.